Vaccines and Global Health: The Week in Review
13 May 2023 :: Issue 703
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19]
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
The WHO Director-General transmits the report of the fifth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the multi-country outbreak of mpox (monkeypox), held on Wednesday 10 May from 12:00 to 17:00 CET.

The Emergency Committee acknowledged the progress made in the global response to the multi-country outbreak of mpox and the further decline in the number of reported cases since the last meeting. The Committee noted a significant decline in the number of reported cases compared to the previous reporting period and no changes in the severity and clinical manifestation of the disease. The Committee acknowledged remaining uncertainties about the disease, regarding modes of transmission in some countries, poor quality of some reported data, and continued lack of effective countermeasures in the African countries, where mpox occurs regularly.

The Committee considered, however, that these are long-term challenges that would be better addressed through sustained efforts in a transition towards a long-term strategy to manage the public health risks posed by mpox, rather than the emergency measures inherent to a public health emergency of international concern (PHEIC).

The Committee emphasised the necessity for long-term partnerships to mobilize the needed financial and technical support for sustaining surveillance, control measures and research for the long-term elimination of human-to-human transmission, as well as mitigation of zoonotic transmissions, where possible. Integration of mpox prevention, preparedness and response within national surveillance and control programmes, including for HIV and other sexually transmissible infections, was reiterated as an important element of this longer-term transition. In particular, the Committee noted that the gains in control of the multi-country outbreak of mpox have been achieved largely in the absence of outside funding support and that longer-term control and elimination are unlikely unless such support is provided. These sustained investments will, in the long run, save money and lives, and reduce the risk of a global resurgence of mpox, as well as the risk of reverse zoonosis resulting in new areas where the virus may circulate.

The WHO Director-General expresses his gratitude to the Chair, Members, and Advisors for their advice and concurs with this advice that the event no longer constitutes a PHEIC for the reasons detailed in the proceedings of the meeting below and issues revised Temporary Recommendations for the transition period, which are presented at the end of this document...
Highlights
:: Since the last situation report published on 27 April 2023, 264 new mpox cases (0.3% increase in total cases) and 10 new related deaths have been reported to WHO.
:: After two weeks with less than 100 cases/week, a slight increase was observed globally in the last week. Most of the new cases are from the WHO Region of the Americas followed by the Western Pacific Region. A slight increase in cases was also observed in the European Region.
:: More countries reported cases in the Western Pacific Region, where, in addition to Japan, China, and the Republic of Korea, cases have also been reported in Australia and Singapore. This report contains more details on the situation in the region.
:: WHO updated its Rapid Risk Assessment for mpox, which assesses the risk at the global level still to be moderate and as well as in most of the regions, except in the Western Pacific and South-East Asia regions where the risk remains low.
:: An updated analysis of mpox genomic sequencing data available from online open-source platform is presented in the report.

PHEIC
Polio

Statement of the thirty-fifth Polio IHR Emergency Committee
12 May 2023  Statement  [Excerpts; Editor’s text bolding]
The thirty-fifth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 3 May 2023 with committee members and advisers attending via video conference, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of global target of eradication of WPV and cessation of outbreaks of cVDPV2 by the end of 2023. Technical updates were received about the situation in the following countries: Afghanistan, Benin, Burundi, the Central African Republic, Chad, the Democratic Republic of the Congo, Indonesia, Pakistan and Somalia...

Conclusion
Although encouraged by the reported progress, the Committee unanimously agreed that the risk of international spread of poliovirus still remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months.

The Committee considered the following factors in reaching this conclusion:

**Ongoing risk of WPV1 international spread:**
Based on the following factors, the risk of international spread of WPV1 remains:
- the ongoing transmission in eastern Afghanistan with cross border spread into Pakistan;
- the large pool of unvaccinated ‘zero dose’ children in southern Afghanistan constitutes an ongoing risk of WPV1 re-introduction into the southern region;
- the importation of WPV1 from Pakistan into Malawi and Mozambique, noting that the exact route the virus took remains unknown;
- sub-optimal immunization coverage achieved during campaigns in southeastern Africa, in Malawi, Mozambique, Zambia and Zimbabwe, meaning there may be insufficient population immunity to halt transmission;
- although surveillance has improved, some gaps in the outbreak response zone means that such transmission may be missed;
- pockets of insecurity and inaccessibility in the remaining endemic transmission zones.

**Ongoing risk of cVDPV2 international spread:**
Based on the following factors, the risk of international spread of cVDPV2 appears to remain high:
- the ongoing outbreaks of cVDPV1 and cVDPV2 in eastern Democratic Republic of the Congo which has caused international spread to neighbouring countries;
- the large outbreak of cVDPV1 particularly in DR Congo and the insufficient number and quality of bOPV immunization response campaigns to date;
- the long distance spread by air travel of cVDPV2 between Israel, the United Kingdom, the USA, and Canada;
- the ever-widening gap in global population intestinal mucosal immunity in young children in many countries since the withdrawal of OPV2 in 2016;
- insecurity and inaccessibility in those areas that are the primary sources of cVDPV transmission.

**Other factors include**
- **Weak routine immunization:** Many countries have weak immunization systems that were further impacted by the COVID-19 pandemic. These services can be further affected by humanitarian emergencies including conflict and protracted complex emergencies poses a continued risk, leaving populations in these fragile areas vulnerable to polio outbreaks.
- **Lack of access:** Inaccessibility continues to be a risk, particularly in northern Yemen and south central Somalia which have sizable populations that have been unreached with polio vaccine for extended periods of more than a year...

**Additional considerations**
The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC and the importance of exploring alternative measures, including instituting a polio IHR Review Committee that could make standing recommendations, and encourages further discussion regarding these alternatives. Nevertheless, the committee felt it was still too early to discontinue the PHEIC as it may send the wrong message at this critical juncture in polio eradication.

Noting the acute humanitarian crises still unfolding in Afghanistan, the committee strongly encouraged house to house campaigns be implemented wherever feasible as these campaigns enhance identification and coverage of zero dose and under-immunized children. The committee noted and strongly supported the ongoing use of female vaccinators, enhancing access to households, with female participation as front line health workers increasing from 10.7% in the October campaign to 12.5% in April.

The ongoing cVDPV2 outbreaks in Indonesia and Israel highlight the importance of sensitive polio surveillance, including environmental surveillance, in all areas where there are high risk sub-populations, and the committee urges all countries to take heed of the lesson learnt and take steps to improve polio surveillance everywhere that such risks exist.
The Committee noted with concern the new conflict areas in Sudan that are disrupting health services and creating a new refugee crisis in neighboring countries. This situation must be closely monitored, as many of the neighboring countries already have cVDPV outbreaks resulting from low essential immunization coverage. More generally, noting the negative impact that the COVID-19 pandemic has had on essential immunization coverage in many of the polio affected countries, the committee stressed the importance of restoring essential immunization coverage. The committee recognized that border vaccination may not be feasible at very porous borders in Africa but was concerned by the lack of synchronization and cross border coordination in response to the WPV1 importation in southeast Africa. The committee also noted with concern that most AFP cases in Mozambique had been detected during campaigns and more systematic surveillance efforts are required including training of clinicians to identify and respond to AFP cases. The committee is concerned by conflicts and insecurity in many of the infected countries as such circumstances allows the polioviruses to elude control in countries such as Yemen, Nigeria, Dr Congo, Mozambique and Sudan.

Overall, the committee once again noted that many of the members states affected by WPV1 or cVDPV outbreaks have either low overall coverage or low subnational coverage.

The committee urged the polio program to continue to address delays in specimens being transported for testing for polioviruses, leading to problems with the reverse cold chain.

Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the Director-General accepted the Committee’s assessment and on 12 May 2023 determined that the poliovirus situation continues to constitute a PHEIC with respect to WPV1 and cVDPV.

The Director-General endorsed the Committee’s recommendations for countries meeting the definition for ‘States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread’, ‘States infected with cVDPV2 with potential risk for international spread’ and for ‘States no longer infected by WPV1 or cVDPV, but which remain vulnerable to re-infection by WPV or cVDPV’ and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective 12 May 2023.

Polio this week as of 10 May 2023 - GPEI

Headlines [Selected]

- After years of engagement with local communities to battle outbreaks and provide essential services, female frontline workers in Pakistan are now being offered a seat at the policymaking table. The benefits are likely to last well after polio is finally defeated. Read more...

- Progress towards polio eradication worldwide, January 2021 to March 2023: published in both this week's CDC's Morbidity and Mortality Weekly Report and WHO's Weekly Epidemiological Record. The co-publication summarises the global programmatic and epidemiological situation, impact and challenges to achieving a sustained world free of all forms of poliovirus, since January 2021 to today.

Summary of new polioviruses this week:

- Pakistan: two WPV1 positive environmental samples
- Chad: one cVDPV2 case
- DR Congo: six cVDPV2 cases
- Madagascar: 17 cVDPV1 positive environmental samples
- Nigeria: three cVDPV2 cases and two cVDPV2 positive environmental samples
- Somalia: one cVDPV2 case

Coronavirus [COVID-19]
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Statement on the fifteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic
5 May 2023  Statement

...During the deliberative session, the Committee members highlighted the decreasing trend in COVID-19 deaths, the decline in COVID-19 related hospitalizations and intensive care unit admissions, and the high levels of population immunity to SARS-CoV-2. The Committee’s position has been evolving over the last several months. While acknowledging the remaining uncertainties posted by potential evolution of SARS-CoV-2, they advised that it is time to transition to long-term management of the COVID-19 pandemic.

The WHO Director-General concurs with the advice offered by the Committee regarding the ongoing COVID-19 pandemic. He determines that COVID-19 is now an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC)...

WHO Weekly Epidemiological and Operational updates
Last update: 10 May 2023

Confirmed cases :: 765 903 278
Confirmed deaths :: 6 927 378
Vaccine doses administered: 13 350 487 934

Weekly epidemiological update on COVID-19 - 11 May 2023
Overview
Globally, over 2.7 million new cases and over 17 000 deaths were reported in the last 28 days (10 April to 7 May 2023), a decrease of 14% and 17%, respectively, compared to the previous 28 days (13 March to 9 April 2023). The picture is mixed at the regional level, with increases in reported cases seen in the South-East Asia and Western Pacific regions and decreases in other regions. As of 7 May 2023, over 765 million confirmed cases and over 6.9 million deaths have been reported globally.
Our World in Data

**Coronavirus (COVID-19) Vaccinations**  [Accessed 13 May 2023]

:: 70% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.38 billion doses have been administered globally, and 209,714 are now administered each day.
:: 29.9% of people in low-income countries have received at least one dose.

---

Global vaccine market report 2022: a shared understanding for equitable access to vaccines - WHO
8 May 2023 :: 47 pages

**Overview**
The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards the Immunization Agenda 2030 and pandemic prevention, preparedness and response efforts. The report is organized in two sections: the first section provides WHO insights on global vaccine market dynamics, drawing from data provided by Member States, which are, in turn, analysed and displayed in the second section.

---

Global Fund Board Reaffirms Strong Commitment Towards Ending Epidemics Amid Growing Threats to Global Health

The Board noted the continued progress in the fight against AIDS, TB and malaria, but pointed to climate change, conflict and anti-LGBTQI+ legislation as dangers in the fight to end the three diseases. 12 May 2023
HA NOI – The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria held its 49th meeting on 10 and 11 May 2023 in Ha Noi, Viet Nam, the first to take place in the Western Pacific region since 2007. The meeting was opened by Ms. Dao Hong Lan, Minister of Health of Viet Nam.

...The Board noted the strong progress against the three diseases in several parts of the world – including progress towards the 95-95-95 HIV targets in Eastern and Southern Africa, the success in fighting drug-resistant malaria in the Greater Mekong region, and the general bounce-back in TB services and metrics – and praised the Global Fund’s contribution to saving over 29 million lives over the 2017-2021 period. The Board also received an update on this year’s disbursements in the current grant cycle, which are on track to surpass the record US$5.2 billion disbursed in 2022 and demonstrate the unprecedented scale, intensity and breadth of grant implementation efforts across the partnership.

Yet Board members expressed concern regarding the global health challenges that risk jeopardizing the delivery of the Sustainable Development Goal 3 objective of health and well-being for all. Climate change and increasing conflict and displacement are affecting the epidemiology and transmission of existing diseases, especially malaria, and increasing the risk that new ones could emerge. In addition, the sharp deterioration of LGBTQI+ rights in numerous countries over the last few months threatens to further impede access to health for communities who already face stigma and discrimination.

“Reducing stigma, discrimination and criminalization of key populations most affected by HIV is a prerequisite for beating AIDS,” said Lady Roslyn Morauta, Vice-Chair of the Global Fund Board. “Punitive laws will fuel the HIV epidemic and endanger the health of entire communities. This is why the Global Fund is committed to breaking down human rights-related barriers that undermine access to health services.”

The Board also stressed the urgent need to reinvigorate both political and technical leadership to address the increasing malaria risks related to climate change and drug or insecticide resistance and get back on track towards malaria elimination. Board members subsequently voted in favor [ download in English ] of increasing risk appetite for malaria interventions while also urging continued vigilance against TB.

Global Fund Executive Director Peter Sands echoed those concerns and urged strengthened partnerships between global players in the face of these current challenges. “We must win a better place for infectious diseases in the climate change agenda,” he said. “Malaria is the iconic example of how climate change is already affecting human health. Tackling malaria needs to be a central component of a more equitable global response to climate change.”...

---

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Editor’s Note:
We observe that OCHA has removed Afghanistan from its listing of “Current Emergencies.” We did not identify any explanation for its removal.
Northern Ethiopia
Ethiopia - Situation Report, 11 May 2023

Somalia
No new digest content identified.

Türkiye/Syria Earthquakes
No new digest content identified.

Ukraine
Last Updated: 10 Feb 2023

WHO & Regional Offices [to 13 May 2023]
https://www.who.int/news
Selected News/Announcements/Statements
12 May 2023  Statement
Statement of the thirty-fifth Polio IHR Emergency Committee

12 May 2023  Departmental news
WHO calls for accelerated action to reduce anaemia

12 May 2023  Departmental news
First-ever WHO research agenda on hand hygiene in health care to improve quality and safety of care

11 May 2023  Statement
Fifth Meeting of the International Health Regulations (2005) (IHR) Emergency Committee
on the Multi-Country Outbreak of mpox (monkeypox)

9 May 2023  News release
152 million babies born preterm in the last decade

9 May 2023  Departmental news
Global progress in tackling maternal and newborn deaths stalls since 2015: UN

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
No new digest content identified.

WHO Region of the Americas PAHO
:: 12 May 2023  Reducing shortage of nurses key to better respond to the next pandemic
PAHO urges governments to invest in more nurses, improve their education and expand their professional role in primary health care. Washington, DC, 12 May 2023 (PAHO)- Between 600,000 and 2 million more health care professionals, including nurses, are needed to meet the health needs of the population of the Americas. On International Nurses Day,...
:: 11 May 2023  **Improved management of hypertension could save 420,000 lives each year in the Americas, PAHO Director says**
Strengthening primary health care services, as well as policies to reduce salt and promote healthy diet and physical activity are key to addressing the risk factors for the biggest killer in the Region.
Washington D.C. 11 May 2023 – In the run-up to World Hypertension Day (17 May), the Pan American Health Organization (PAHO) Director, Dr. Jarbas...
:: 11 May 2023  **PAHO brings together experts to review strategies to tackle outbreaks in the Americas**
Panama City, Panama, 11 May 2023 (PAHO)- The Pan American Health Organization (PAHO) recently brought together a group of experts to review strides in outbreak management in the Region, along with plans to support countries in infectious disease detection and control in the face of growing epidemics, many originating from animals. The meeting of...

**WHO South-East Asia Region** SEARO
:: 11 May 2023  **Bangladesh eliminates lymphatic filariasis**
13 May 2023  News release
In a boost to efforts to end neglected tropical diseases in WHO South-East Asia Region, Bangladesh has eliminated lymphatic filariasis, a disease that cripples and has significant social and economic impact on the affected communities.

**WHO European Region** EURO
:: 11 May 2023  News release
**Rebuilding primary health-care services after the February 2023 earthquakes: addressing women’s reproductive health in Türkiye**
:: 11 May 2023  Statement
**Statement – Dr Hans Henri P. Kluge, WHO Regional Director for Europe, at the 9th High-level Meeting of the Small Countries Initiative**

**WHO Western Pacific Region**
*No new digest content identified.*

----------

**Disease Outbreak News (DONs)**
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

**8 May 2023 | Marburg virus disease - Equatorial Guinea and the United Republic of Tanzania**

----------

**New WHO Publications**
https://www.who.int/publications/i
Selected
12 May 2023
Accelerating anaemia reduction: a comprehensive framework for action

11 May 2023
The generic all-hazards risk assessment and planning tool for mass gathering events

11 May 2023
Report of the sixth meeting of the WHO Onchocerciasis Technical Advisory Subgroup: virtual meeting, 19-21...

10 May 2023
WHO framework for meaningful engagement of people living with noncommunicable diseases, and mental health...

8 May 2023
Global vaccine market report 2022: a shared understanding for equitable access to vaccines

US – HHS, FDA, CDC

HHS

News

HHS Secretary Xavier Becerra Statement on End of the COVID-19 Public Health Emergency
May 11, 2023 News Release

...Based on current COVID-19 trends, the Department of Health and Human Services (HHS) is planning for the federal Public Health Emergency (PHE) for COVID-19, declared under Section 319 of the Public Health Service (PHS) Act, to expire at the end of the day on May 11, 2023.

Since HHS Secretary Xavier Becerra’s February 9, 2023, letter to Governors announcing the planned end of the COVID-19 PHE, the Department has been working closely with partners—including Governors; state, local, Tribal, and territorial agencies; industry; and advocates—to ensure an orderly transition out of the COVID-19 PHE.

Today, HHS is releasing a Fact Sheet with an update on current flexibilities enabled by the COVID-19 emergency declaration and how they will be impacted by the end of the COVID-19 PHE on May 11.

HHS Fact Sheet: Telehealth Flexibilities and Resources and the COVID-19 Public Health Emergency
May 10, 2023 News Release

Letter to U.S. Governors from HHS Secretary Xavier Becerra On planning for the COVID-19 PHE
May 10, 2023 News Release

Fact Sheet: End of the COVID-19 Public Health Emergency
May 9, 2023 News Release
Based on current COVID-19 trends, the Department of Health and Human Services (HHS) is planning for the federal Public Health Emergency (PHE) for COVID-19, declared under Section 319 of the Public Health Service (PHS) Act, to expire at the end of the day on May 11, 2023.

Since HHS Secretary Xavier Becerra’s February 9, 2023, letter to Governors announcing the planned end of the COVID-19 PHE, the Department has been working closely with partners—including Governors; state, local, Tribal, and territorial agencies; industry; and advocates—to ensure an orderly transition out of the COVID-19 PHE.

Today, HHS is releasing a Fact Sheet with an update on current flexibilities enabled by the COVID-19 emergency declaration and how they will be impacted by the end of the COVID-19 PHE on May 11...

**FDA**

**Press Announcements**

**FDA Roundup: May 12, 2023**

::...On Thursday, the FDA published the FDA Voices: “Lessons Learned from COVID-19 Are Informing Preparation for Future Public Health Emergencies,” by Robert M. Califf, M.D., Commissioner of Food and Drugs and Hilary Marston, M.D., M.P.H., Chief Medical Officer. The U.S. Department of Health and Human Services is planning for the federal Public Health Emergency for COVID-19 declared under the Public Health Service Act to expire on May 11, 2023. COVID-19 remains a high priority and the FDA will remain engaged with numerous activities to protect and promote public health. And while the virus is still with us, causing illness and death in some cases, the good news is we now have more tools to help protect many in our families and communities from the most harmful impacts of COVID-19.

:: On Wednesday, the FDA announced a joint project with the National Institute of Standards and Technology that aims to develop tools that developers will be able to use to identify unintended effects of genome editing in animals. These science-based tools will add to the base of knowledge for all developers and regulators.

:: On Wednesday, the FDA issued a discussion paper, “Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products.” The discussion paper is intended to initiate communication on artificial intelligence and machine learning (AI/ML) with stakeholders, including industry and academia, to promote mutual learning and discussion. The agency is soliciting feedback on the opportunities and challenges of using AI/ML in drug development and medical device development for drugs to inform future guidance on AI/ML in drug development. For more information on the discussion paper and how to comment, please see the Federal Register notice and visit the Artificial Intelligence and Machine Learning for Drug Development webpage.

**FDA VRBPAC**

**Advisory Committee Calendar**

**Vaccines and Related Biological Products Advisory Committee May 18, 2023 Meeting Announcement - 05/18/2023**

On May 18, 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.

**CDC/ACIP [U.S.] [to 13 May 2023]**

http://www.cdc.gov/media/index.html
ACIP Meetings
Next ACIP Meeting: June 21-22

MMWR Weekly
https://www.cdc.gov/mmwr/index2023.html
May 12, 2023 / No.19  Selected content
PDF of this issue
- Progress Toward Poliomyelitis Eradication — Worldwide, January 2021–March 2023
- COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration — United States, May 11, 2023
- Correlations and Timeliness of COVID-19 Surveillance Data Sources and Indicators — United States, October 1, 2020–March 22, 2023

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries [Selected]
5/11/23
COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration — United States, May 11, 2023

Europe

European Medicines Agency [EMA]
News & Press Releases
News: EMA and European medicines regulatory network lift COVID-19 business continuity status (new)
Last updated: 10/05/2023

EMA and the European medicines regulatory network are lifting their respective COVID-19 business continuity measures after successfully handling the unprecedented operational challenges posed by the pandemic. This was foreseen in EMA’s workplan for 2023-2025.

‘Throughout the pandemic we proved time and again that public health was our priority and ensured that patients in Europe could continue to have access to the newest, highest-quality therapeutics and vaccines,’ said Emer Cooke, EMA’s Executive Director. ‘Now that the peak of the pandemic has passed, the time is right for EMA and the network to close our business continuity measures. Our approach during the pandemic ensured that we could accelerate the assessment of therapeutics and vaccines for COVID-19 in an unprecedented manner while keeping assessment times for non-COVID products on schedule.’...

News: Statement from Emer Cooke on the end of the COVID-19 public health emergency (new)
Last updated: 08/05/2023
From the EU and EMA perspective, we have much to be proud of in the way we responded: the EU Vaccine Strategy made sure that each and every EU country was able to have access to safe, effective and high-quality vaccines and therapeutics to protect their citizens. EMA provided robust scientific recommendations, timely evaluation of new vaccines and therapeutics - adapting its recommendations as the virus evolved - and helped mitigate shortages.

Throughout the pandemic, waves of disinformation undermined trust in our work and scientific expertise and, ultimately put millions of lives at risk. We shouldn’t forget that it was science that brought us the vaccine breakthroughs, it was science that freed us from the lockdowns, and it was scientists who provided the trusted, factual information when it mattered most.

Overall, EMA initiated new and agile ways of working, many of which are here to stay. Our response was built on unprecedented collaboration and a united sense of purpose across regulators, developers, institutions and citizens. It was supported by the tireless commitment and work of countless experts from the regulatory authorities – at EMA and at national level. These activities were underpinned by a fruitful collaboration between international regulators through the International Coalition of Medicines Regulatory Authorities (ICMRA).

But our work does not stop here. COVID-19 remains a global health threat, and with the risk of emergence of new variants, we cannot let our guard down. EMA remains fully committed to supporting the EU response to the COVID-19 threat and ensuring that new or adapted vaccines and therapeutics can be made available as needed...

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports [Selected]
News
Weekly COVID-19 country overview
Epidemiological update - 11 May 2023

Africa CDC [to 13 May 2023]
http://www.africacdc.org/
News
The Transition Beyond the Acute Phase of COVID-19 Pandemic in Africa
9 May 2023
WHO Lifts the Status of coronavirus disease (COVID-19) Pandemic as a Public Health Emergency of International Concern (PHEIC)
...The Africa Centers for Disease Control and Prevention (Africa CDC) welcomes this strategic shift recognizing the significance of transitioning to long-term control strategies. The African Union through the Africa CDC has offered its member states comprehensive strategic, technical, and logistical assistance. This support has effectively helped guide the severe health impacts and fatalities that were initially anticipated for the continent...

“To continuously lessen the impact of COVID-19 on our continent, I implore the African Union member states to maintain different approaches in scaling up COVID-19 vaccinations such as primary and booster COVID-19 vaccination to all vulnerable populations and enhance our efforts in saving lives and
livelihoods. This will enhance our level of preparedness in the event of any COVID-19 surges,”— Dr Jean Kaseya, Africa CDC Director General...

-----

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 13 May 2023]
http://en.nhc.gov.cn/
News
No new digest content identified.

National Medical Products Administration — PRC [to 13 May 2023]
http://english.nmpa.gov.cn/
News
NMPA holds meeting to review vaccine regulation and quality management system
2023-05-11
On May 4, the National Medical Products Administration (NMPA) held a review meeting on the vaccine regulation and quality management system in 2022, to summarize the construction and operation of the system, evaluate its appropriateness, effectiveness and adequacy, and make arrangements for the key tasks in the next stage.

Officials stress sound implementation of Class B management of COVID
2023-05-09
Chinese health officials have stressed the sound implementation of measures to manage COVID-19 as a Class B infectious disease, after the World Health Organization said the pandemic no longer constitutes a Public Health Emergency of International Concern.

China's COVID fight a guidebook for the future
2023-05-09
China took the lead in sharing COVID-19 information and virus control experience, as well as in supplying vaccines and sending medical teams, during the global fight against the disease, experts and officials said on Monday, after the World Health Organization announced the downgrading of the pandemic last week.

China CDC Weekly Reports: Current Volume (5)
2023-05-12 / No. 19 Selected
View Pdf of this issue
- Preplanned Studies: Survey on Immunization Services for Children with Medical Conditions — China, 2022

-----

Organization Announcements
No new digest content identified.
The need for speed: CEPI seeks to fast-track vaccine manufacturing in response to a new disease outbreak

CEPI launches new Call for Proposals which aims to identify technologies that can speed up the manufacturing of vaccines as a critical part of its 100 Days Mission

09 May 2023

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 13 May 2023]
https://cioms.ch/
News; Publications; Events

CIOMS Cumulative Glossary, with a focus on Pharmacovigilance (Version 2.1)

The CIOMS Cumulative Glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance. It includes links to the reports and, where applicable, provides references to the sources from which the definitions were adopted or modified. Version 2.1 covers the terms included in thirteen different CIOMS reports published between 1992 and 2022. It does not cover CIOMS reports on the subjects of ethics, clinical pharma...

Year of publication: 2023  Number of pages: 144  SKU: 7912

Gender considerations in health research
The meeting report is now available from the CIOMS / GENDRO joint meeting held on 2 February 2023.

CIOMS Glossary of ICH terms and definitions: Version 3 now available

Version 3 of the CIOMS Glossary of ICH terms and definitions is now freely available here. It can also be accessed from the ICH webpage here.

DARPA – Defense Advanced Research Projects Agency [U.S.]  [to 13 May 2023]
https://www.darpa.mil/news
News

No new digest content identified.

Duke Global Health Innovation Center  [to 13 May 2023]
https://dukeghic.org/
Our Blog

No new digest content identified.

EDCTP  [to 13 May 2023]
http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

**Emory Vaccine Center**  [to 13 May 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

**European Vaccine Initiative**  [to 13 May 2023]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

**Evidence Aid**  [to 13 May 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
No new digest content identified.

**Fondation Merieux**  [to 13 May 2023]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

**Gavi**  [to 13 May 2023]
https://www.gavi.org/
News Releases
No new digest content identified.

**GHIT Fund**  [to 13 May 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
May 10, 2023
**GHIT Fund Secures USD 24 million pledge from Bill & Melinda Gates Foundation over 3 years**

**Global Fund**  [to 13 May 2023]
News & Stories
12 May 2023
Global Fund Board Reaffirms Strong Commitment Towards Ending Epidemics Amid Growing Threats to Global Health
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria held its 49th meeting on 10 and 11 May 2023 in Ha Noi, Viet Nam, the first to take place in the Western Pacific region since 2007.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 13 May 2023]
https://www.gloid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 13 May 2023]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 13 May 2023]
https://www.hhmi.org/news
Press Room
Institute May 9 2023
HHMI Names 31 Inaugural Freeman Hrabowski Scholars
HHMI announces the inaugural Freeman Hrabowski Scholars cohort — 31 exceptional early career faculty who have potential to become leaders in their research fields and to create diverse and inclusive lab environments in which everyone can thrive.

Human Vaccines Project [to 13 May 2023]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI [to 13 May 2023]
https://www.iavi.org/
Latest News
FEATURES May 10, 2023
New IAVI paper makes the case for strengthening clinical and regulatory pathways to accelerate global access to monoclonal antibodies

INSERM [to 13 May 2023]
https://www.inserm.fr/en/home/
Press Releases
No new digest content identified.
South Sudan: ICRC introduces disease-resistant cassava varieties to combat food shortage

The endorsement came after successful testing and analysis of the new varieties by an expert team of the MAFS. Cassava, a root crop, remains one of the main staple foods in many parts of South Sudan.

Table of National Committees and other national bodies on international humanitarian law

States face a formidable task when it comes to implementing international humanitarian law (IHL) within the domestic legal order. This table contains information on all existing national committees and other national bodies on IHL.

IFFIm

Press Releases/Announcements
No new digest content identified.

IFRC [to 13 May 2023]
Press Releases [Selected]
Press release 13/05/2023
Myanmar Red Cross prepares ahead landfall of Cyclone Mocha

Press release 10/05/2023
Jagan Chapagain renewed as IFRC Secretary General
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

**Blogs**

**Guiding the Future of Science: introducing the Centre for Science Futures**
11.05.2023
The Centre for Science Futures will operate as a think tank within the International Science Council, aiming to improve our understanding of current trends in science and research systems, and to provide options and tools for appropriate action.

**International Union of Immunological Societies (IUIS)**
[https://iuis.org/](https://iuis.org/)
News/Events [Selected]
No new digest content identified.

**IVAC** [to 13 May 2023]
Updates; Events
No new digest content identified.

**IVI** [to 13 May 2023]
[http://www.ivi.int/](http://www.ivi.int/)
IVI News & Announcements
No new digest content identified.

**Johns Hopkins Center for Health Security** [to 13 May 2023]
Center News [Selected]
News [Selected]
**Center Director Tom Inglesby Co-Authors Guest Essay in The New York Times About US CDC Reform**
May 8, 2023

**MSF/Médecins Sans Frontières** [to 13 May 2023]
http://www.msf.org/
Latest [Selected Announcements]
Refugees, IDPs and people on the move
**EU leaders continue to push through deadly policies for migrants**
Project Update 12 May 2023

Central American Migration
**End of Title 42 will not end crisis for migrants**
Press Release 12 May 2023
Conflict in Sudan

Refugees seeking safety in Sudan trapped in another stream of violence
Project Update 11 May 2023

Kiribati

People in Kiribati threatened by climate crisis and multiple health threats
Project Update 10 May 2023

Haiti

People trapped by violence in need of medical assistance
Project Update 10 May 2023

National Academy of Medicine - USA [to 13 May 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 13 May 2023]
https://www.nationalacademies.org/newsroom?
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 13 May 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee (NVAC)
June 15-16, 2023 NVAC Meeting

NIH [to 13 May 2023]
http://www.nih.gov/
News Releases
Scientists release a new human “pangenome” reference
May 10, 2023 — More complete and sophisticated collection of genome sequences captures significantly more human diversity.

PATH [to 13 May 2023]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

Rockefeller Foundation [to 13 May 2023]
Selected Reports/Press Releases

Press Releases

Makerere University School of Public Health Receives USD $100,000 Donation From The Rockefeller Foundation for New Building
05.08.23

Sabin Vaccine Institute [to 13 May 2023]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS [to 13 May 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
Press release
UNAIDS calls for access to HIV prevention, treatment and care in prisons, including access to life saving harm reduction services
Harm reduction policies and practices help people who are using drugs to stay alive and protect them from HIV and Hepatitis C
Released ahead of International Harm Reduction Day - 7 May 2023

UNICEF [to 13 May 2023]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements
Statement 13 May 2023
Statement by UNICEF Executive Director Catherine Russell on escalation of hostilities in Israel and the State of Palestine
NEW YORK, 13 May 2023 – "Escalating violence in and around the Gaza Strip is once again wreaking havoc on the lives of children. "At least six children – the youngest just four-years-old – have been killed and 36 reported injured in the Gaza Strip since 9 May. All schools in the Gaza Strip are closed, as well as those in Israel within 40 km,...

News note 12 May 2023
Another Bitter Blow for Children in Sudan
Geneva, 12 May 2023 – "The factory in Khartoum which produces therapeutic food for children in Sudan suffering the most dangerous form of malnutrition has been burnt down. "The fire destroyed 14,500 cartons of Ready to Use Therapeutic Food (RUTF). This was set to be transported to locations for the life-saving treatment of 14,500 children. "This..."
NEW YORK, 11 May 2023 – “Migrant children have the right to request asylum, to be protected from harm and to be with their families. “UNICEF hopes that the lifting of the public-health related asylum restrictions at the U.S.-Mexico border under Title 42 will help to restore and safeguard those rights. “We commend recent efforts to provide children...

Press release 11 May 2023
Sudan violence forces at least 450,000 children to flee their homes

NEW YORK/AMMAN/NAIROBI/DAKAR, 11 May 2023 – UNICEF is stepping up humanitarian support for children on the move affected by the ongoing conflict in Sudan. As violence continues, an estimated 82,000 children have fled to neighbouring countries and approximately 368,000 more are newly displaced inside the country. According to UNHCR, more than 164,...

Press release 11 May 2023
Armed violence plunging children into severe acute malnutrition in Haiti

PORT-AU-PRINCE/PANAMA/NEW YORK, 11 MAY 2023 – Armed violence has intensified the number of children in Haiti suffering from severe acute malnutrition (SAM), also known as severe wasting, which has skyrocketed in the country by 30 percent compared to 2022, UNICEF has warned today. A national nutrition Standardized Monitoring and Assessment of...

Press release 09 May 2023
150 million babies born preterm in the last decade

Of every 10 babies born, 1 is preterm – and every 40 seconds, 1 of those babies dies Preterm birth rates have not changed in the past decade in any region of the world The impacts of conflict, climate change, COVID-19 are increasing risks for women and babies everywhere Action is needed urgently to improve the prevention of preterm birth,...

Press release 08 May 2023
Global progress in tackling maternal and newborn deaths stalls since 2015: UN

GENEVA/NEW YORK, 9 May 2023 – Global progress in reducing deaths of pregnant women, mothers and babies has flatlined for eight years due to decreasing investments in maternal and newborn health, according to a new report from the United Nations (UN). The report shows that over 4.5 million women and babies die every year during pregnancy,...

Unitaid [to 13 May 2023]

No new digest content identified.
Vaccine Equity Cooperative [nee Initiative]  [to 13 May 2023]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin]  [to 13 May 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
Recovering Lost Gains in Routine Childhood Immunization
May 12, 2023
by: Danielle Countryman, Theresa Sommers, PhD, MPH
The Sabin Vaccine Institute’s Vaccine Acceptance & Demand initiative is proud to provide funding to 7 grant partners awarded through the 2023-2024 Social and Behavioral Research Grants Program. This blog is the first in a series examining the selected research projects based on one of three themes: zero-dose children, life-course immunization, and operationalizing of the WHO BeSD Framework.

Vaccine Confidence Project  [to 13 May 2023]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 13 May 2023]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

Wellcome Trust  [to 13 May 2023]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

The Wistar Institute  [to 13 May 2023]
Press Releases
May. 10, 2023
GeneOne and Wistar Institute Collaborate to Develop Small Molecule Therapeutics to Protect Humans from Nipah Virus
Collaboration to develop small molecules targeting Nipah virus as next generation therapies.

WFPHA: World Federation of Public Health Associations  [to 13 May 2023]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.
World Medical Association [WMA]  [to 13 May 2023]
Press Releases
No new digest content identified.

World Organisation for Animal Health (OIE)  [to 13 May 2023]
https://www.oie.int/en/
Press Releases, Statements
News
WOAH to hold its 90th General Session the 21-25 May
Published on 11 May 2023

-----

ARM [Alliance for Regenerative Medicine]  [to 13 May 2023]
Selected Press Releases
No new digest content identified.

BIO  [to 13 May 2023]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 13 May 2023]
http://www.dcvmn.org/
News; Upcoming events
May 10, 2023
DCVMN at the 17th World Congress on Public Health (WCPH)

ICBA – International Council of Biotechnology Associations  [to 13 May 2023]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 13 May 2023]
https://ifpma.org/
Selected Press Releases, Statements, Publications
Statement  9 May 2023
IFPMA statement at the Multi-stakeholder Hearing on Pandemic Prevention, Preparedness, and Response
Statement  9 May 2023
**IFPMA statement at the Multi-stakeholder Hearing on Universal Health Coverage**

Statement  8 May 2023
**IFPMA statement for Multi-stakeholder Hearing on Tuberculosis**

**International Alliance of Patients’ Organizations – IAPO** [to 13 May 2023]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]

**Save the date: 10th Global Patients Congress**
We are delighted to announce that IAPO’s 10th Global Patients Congress (GPC 2023) - "Innovative patient partnerships at the heart of global health advancement" will be held on 19 - 20 May 2023 at the Maison Internationale des Associations (MIA) in Geneva, Switzerland as a hybrid event.

**International Generic and Biosimilar Medicines Association [IGBA]**
https://www.igbamedicines.org/
News
No new digest announcements identified

**PhRMA**  [to 13 May 2023]
http://www.phrma.org/
Press Releases
No new digest announcements identified

::::
::::

**Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements**

**AstraZeneca**
Press Releases - No new digest announcements identified

**Bharat Biotech**
Press Releases - No new digest announcements identified

**BioCubaFarma** – Cuba
Últimas Noticias - Website not responding at inquiry

**Biological E**
News - No new digest announcements identified

**BioNTech**
Press Releases - No new digest announcements identified
Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News
IV International Symposium Cancer 2023
Varadero, Cuba, September, 2023

Cinnagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News
May 8, 2023
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media
12 May 2023
GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
...: Only investigational 5-in-1 vaccine with demonstrated immunological effectiveness against 110 diverse MenB invasive strains in a clinical trial
:: If approved, this vaccine candidate could provide the broadest coverage against the most prevalent meningococcal serogroups and could lead to a simplified immunisation schedule

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Merck
News releases - No new digest announcements identified

Moderna
Press Releases - No new digest announcements identified
Nanogen
*News* - No new digest announcements identified

Novartis
*News* - No new digest announcements identified

Novavax
*Press Releases*
May 12, 2023
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

May 9, 2023
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses

Pfizer
*Recent Press Releases* - No new digest announcements identified

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
*Press Releases*
May 12, 2023  Press releases
Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
- HARMONIE Phase 3b data reinforce nirsevimab’s consistent and high efficacy against infant hospitalizations due to RSV
- Data presented at ESPID add to the body of evidence demonstrating nirsevimab’s protection against RSV-related lower respiratory tract disease (LRTD) and confirm its favorable safety profile in multi-country, real-world conditions

Serum Institute of India
*NEWS & ANNOUNCEMENTS* - No new digest announcements identified

Sinopharm/WIBPBP
*News* - No new digest announcements identified

Sinovac
*Press Releases* - No new digest announcements identified

SK Biosciences
*Press Releases* - No new digest announcements identified
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 14, 2023  Issue 2
https://www.tandfonline.com/toc/uabr21/current

Article

A Content Analysis of Self-Reported Financial Relationships in Biomedical Research
S. Scott Graham, Nandini Sharma, Martha S. Karnes, Zoltan P. Majdik, Joshua B. Barbour & Justin F. Rousseau
Pages: 91-98
Published online: 28 Dec 2022
Article

Ensuring the Scientific Value and Feasibility of Clinical Trials: A Qualitative Interview Study
Walker Morrell, Luke Gelinas, Deborah Zarin & Barbara E. Bierer
Pages: 99-110
Published online: 04 Jan 2023

AMA Journal of Ethics
Volume 25, Number 5: E305-379 May 2023
https://journalofethics.ama-assn.org/issue/ipe-and-innovation

IPE and Innovation
Interprofessional education (IPE) began as a health and social care movement in the early 1970s and took firm hold in US-based accreditation standards in the mid-2000s. IPE should start early in health professions education and prepare clinicians for cross-disciplinary work culture that nourishes quality, collegiality, and safety in a rapidly evolving health sector. Since formation of the Interprofessional Education Collaborative®, IPE trends have gained momentum. This theme issue considers strategies for wider implementation of educational innovations that promote patient-centered and collaborative care, reduce iatrogenic harm, and improve health outcomes.

American Journal of Infection Control
May 2023 Volume 51 Issue 5 p481-602
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
May 2023 Volume 64 Issue 5 p611-780
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Public Health
May 2023 113(5)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
https://www.ajtmh.org/view/journals/tpmd/108/5/tpmd.108.issue-5.xml
[Reviewed earlier]

Annals of Internal Medicine
April 2023 Volume 176, Issue 4
http://annals.org/aim/issue
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

The aims of this research were to provide a better understanding of the specific evidence needs for assessment of clinical and cost-effectiveness of cell and gene therapies, and to explore the extent that the ...

Authors: Michael Drummond, Oriana Ciani, Giulia Fornaro, Claudio Jommi, Eva Susanne Dietrich, Jaime Espin, Jean Mossman and Gerard de Pouvourville

Citation: BMC Health Services Research 2023 23:484

Content type: Research Published on: 13 May 2023

Medical and public health professionals’ perceived facilitators and barriers of human papillomavirus (HPV) vaccination among African American adolescents in Shelby County, Tennessee

Human papillomavirus (HPV) infects nearly 85% of sexually active Americans during their lifetime, causing most cervical and five other cancers. Routine HPV vaccination is recommended for adolescents to prevent...

Authors: Seok Won Jin, Daniel Cruz Lattimore, Eric Harlin, Levonna Davis, Virginia Erholtz and Heather M. Brandt

Citation: BMC Health Services Research 2023 23:469

Content type: Research Published on: 10 May 2023

Community engagement processes in low- and middle-income countries health research settings: a systematic review of the literature
Community Engagement is an important ethical imperative in research. Although substantial research emphasizes its real value and strategic importance, much of the available literature focuses primarily on the ...

Authors: Zinhle Mthembu, John J. O. Mogaka and Moses J. Chimbari
Citation: BMC Health Services Research 2023 23:457
Content type: Research Published on: 8 May 2023

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 13 May 2023)
COVID-19 vaccine hesitancy and social contact patterns in Pakistan: results from a national cross-sectional survey
Vaccination is a key tool against COVID-19. However, in many settings it is not clear how acceptable COVID-19 vaccination is among the general population, or how hesitancy correlates with risk of disease acqui...
Authors: Matthew Quaife, Sergio Torres-Rueda, Zlatina Dobreva, Kevin van Zandvoort, Christopher I. Jarvis, Amy Gimma, Wahaj Zulfiqar, Muhammad Khalid and Anna Vassall
Citation: BMC Infectious Diseases 2023 23:321
Content type: Research article Published on: 11 May 2023

Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies
Numerous vaccination research experiments have been conducted on non-primate hosts to prevent or control HTLV-1 infection. Therefore, reviewing recent advancements for status assessment and strategic planning ...
Authors: Niloofar Seighali, Arman Shafiee, Mohammad Ali Rafiee, Dlnya Aminzade and Sayed-Hamidreza Mozhgani
Citation: BMC Infectious Diseases 2023 23:320
Content type: Research article Published on: 11 May 2023

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 13 May 2023)
[No new digest content identified]

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 13 May 2023)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 13 May 2023)
COVID-19 mRNA vaccination status and concerns among pregnant women in Japan: a multicenter questionnaire survey
mRNA vaccination is an effective, safe, and widespread strategy for protecting pregnant women against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, information...
Authors: Ken Takahashi, Osamu Samura, Akihiro Hasegawa, Haruna Okubo, Keiji Morimoto, Madoka Horiya, Aikou Okamoto, Daigo Ochiai, Mamoru Tanaka, Masaki Sekiguchi, Naoyuki Miyasaka, Yuto Suzuki, Tsutomu Tabata, Eijiro Hayata, Masahiko Nakata, Tomoo Suzuki...
Citation: BMC Pregnancy and Childbirth 2023 23:332
Content type: Research Published on: 9 May 2023

Inequity of antenatal influenza and pertussis vaccine coverage in Australia: the Links2HealthierBubs record linkage cohort study, 2012–2017
Pregnancy and early infancy are increased risk periods for severe adverse effects of respiratory infections. Aboriginal and/or Torres Strait Islander (respectfully referred to as First Nations) women and child...
Authors: Lisa McHugh, Annette K Regan, Mohinder Sarna, Hannah C Moore, Paul Van Buynder, Gavin Pereira, Christopher C Blyth, Karin Lust, Ross M Andrews, Kristy Crooks, Peter Massey and Michael J Binks
Citation: BMC Pregnancy and Childbirth 2023 23:314
Content type: Research Published on: 8 May 2023

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 13 May 2023)
Exploring the vaccine conversation on TikTok in Italy: beyond classic vaccine stances
TikTok, a social media platform for creating and sharing short videos, has seen a surge in popularity during the COVID-19 pandemic. To analyse the Italian vaccine conversation on TikTok, we downloaded a sample...
Authors: Lorenza Parisi, Simone Mulargia, Francesca Comunello, Vittoria Bernardini, Arianna Bussoletti, Carla Rita Nisi, Luisa Russo, Ilaria Campagna, Barbara Lanfranchi, Ileana Croci, Eleonora Grassucci and Francesco Gesualdo
Citation: BMC Public Health 2023 23:880
Content type: Research Published on: 12 May 2023

Factors influencing and changes in childhood vaccination coverage over time in Bangladesh: a multilevel mixed-effects analysis
This study aimed to investigate the associated factors and changes in childhood vaccination coverage over time in Bangladesh.
Citation: BMC Public Health 2023 23:862
Content type: Research Published on: 11 May 2023

Determinants of COVID-19 vaccination decision among Filipino adults
With a number of vaccines against COVID-19 now widely available globally, it is opportune to determine what tips the decision to get vaccinated. In most countries like the Philippines where the government prov...

Authors: Lourdes Marie Sequerra Tejero, Rosemary Ruiz Seva, Bettina Joyce Petelo Ilagan and Kattleea Loreza Almajose
Citation: BMC Public Health 2023 23:851
Content type: Research Published on: 10 May 2023

BMC Research Notes
http://www.biomedcentral.com/bmcresearchnotes/content
(Reviewed earlier)
[No new digest content identified]

BMJ Evidence-Based Medicine
April 2023 - Volume 28 - 2
https://ebm.bmj.com/content/28/2
[Reviewed earlier]

BMJ Open
May 2023 - Volume 13 - 5
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

Bulletin of the Atomic Scientists
May 2023
https://thebulletin.org/magazine/2023-05/
[New issue; No digest content identified]

Bulletin of the World Health Organization
Volume 101(5); 2023 May 1
https://www.ncbi.nlm.nih.gov/pmc/issues/434533/
[Reviewed earlier]

Cell
Apr 27, 2023 Volume 186 Issue 9 p1817-2040
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
Volume 49, Issue 3 Pages: 407-616 May 2023
https://onlinelibrary.wiley.com/toc/13652214/current
The Alendronate Conundrum: Balancing the Competing Influences for Truly Informed Consent About Drug Safety in an Era of Rapid Change
Marcia M. Boumil, Paul R. Beninger
Published online: March 28, 2023
p376-381
Abstract
This commentary highlights critical decision points regarding the responsibilities of the key stakeholders—pharmaceutical companies, the US Food and Drug Administration, clinicians, and patients—regarding the communication of the risk of a medication. It addresses responsibility for remaining current about emerging drug reactions that often cannot be appreciated during the initial approval period of new drugs and biologics. Further complicating the issue are the medical systems that limit a clinician's time and bandwidth to keep abreast of emerging adverse reactions and to engage in an informed consent process with a lay patient who often has a limited understanding of medical terms and quantitative methods that can provide context for understanding rare complications and adverse drug reactions. Nevertheless, the risk of not finding an amenable way forward for all stakeholders is a descent into the unending crippling malpractice settlements that will only inexorably raise the costs of health care and encourage the exodus of clinicians from the profession.

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 13 May 2023]
[No new digest content identified]
The CRISPR Journal  
Volume 6, Issue 2 / April 2023  
https://www.liebertpub.com/toc/crispr/6/2  
[Reviewed earlier]

Current Genetic Medicine Reports  
Volume 10, issue 3, September 2022  
https://link.springer.com/journal/40142/volumes-and-issues/10-3  
[Reviewed earlier]

Current Medical Research and Opinion  
Volume 39, Issue 5  2023  
https://www.tandfonline.com/toc/icmo20/current  
[New issue; No digest content identified]

Current Opinion in Infectious Diseases  
June 2023 - Volume 36 - Issue 3  
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx  
[Reviewed earlier]

Current Protocols in Human Genetics  
Volume 108, Issue 1  December 2020  
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current  
[Reviewed earlier]

Developing World Bioethics  
Volume 23, Issue 1  Pages: 1-87  March 2023  
https://onlinelibrary.wiley.com/toc/14718847/current  
[Reviewed earlier]

Development in Practice  
Volume 33, Issue 3, 2023  
http://www.tandfonline.com/toc/cdip20/current  
[Reviewed earlier]

Development Policy Review  
Volume 41, Issue 3  May 2023  
https://onlinelibrary.wiley.com/toc/14677679/current  
[Reviewed earlier]
Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 2  Pages: 245-542  April 2023
https://onlinelibrary.wiley.com/toc/14677717/2023/47/2
[Reviewed earlier]

EMBO Reports
Volume 24  Issue 5  4 May 2023
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 5—May 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 42  March 2023
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 45, Issue 2  Pages: 1-42  March–April 2023
https://onlinelibrary.wiley.com/toc/25782363/current
:: Conflicts of interest :: Surrogate consent and decisional impairment
[Reviewed earlier]

Ethics & International Affairs
Volume 37 - Issue 1 - Spring 2023
Ethics, Medicine and Public Health
Volume 27, April 2023
[Reviewed earlier]

The European Journal of Public Health
Volume 33, Issue 2, April 2023
https://academic.oup.com/eurpub/issue/33/2
[Reviewed earlier]

Expert Review of Vaccines
Vol 22 (1) 2023 Issue In Progress
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
May/June 2023 Volume 102, Number 3
https://www.foreignaffairs.com/issues/2023/102/3
[New issue; No digest content identified]

Forum for Development Studies
Volume 50, 2023 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[New issue; No digest content identified]

Genetics in Medicine
Volume 25, Issue 5 May 2023
[Reviewed earlier]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 13 May 2023]
[No new digest content identified]

Global Health Action
Volume 16, Issue 1 (2023)
Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 13 May 2023]
[No new digest content identified]

Health and Human Rights
Volume 25, Issue 1, June 2023,
https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/

Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks

...The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...
Feasibility and sustainability of a school-based platform for integrated delivery of HPV vaccination with adolescent health services in Tanzania: qualitative insights from stakeholders
Joseph G Rosen and others
Health Policy and Planning, Volume 38, Issue 4, May 2023, Pages 486–495,
https://doi.org/10.1093/heapol/czad014

Barriers to cervical cancer and breast cancer screening uptake in low- and middle-income countries: a systematic review
Ananth Srinath and others
Health Policy and Planning, Volume 38, Issue 4, May 2023, Pages 509–527,
https://doi.org/10.1093/heapol/czac104
[Reviewed earlier]

**JAMA**
May 9, 2023, Vol 329, No. 18, Pages 1539-1618
https://jamanetwork.com/journals/jama/currentissue
[New issue; No digest content identified]

**JAMA Health Forum**
May 2023, Vol 4, No. 5
https://jamanetwork.com/journals/jama-health-forum/issue
[Reviewed earlier]

**JAMA Pediatrics**
May 2023, Vol 177, No. 5, Pages 445-547
https://jamanetwork.com/journals/jamapediatrics/currentissue
[New issue; No digest content identified]

**JBI Evidence Synthesis**
April 2023 - Volume 21 - Issue 4
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

**Journal of Adolescent Health**
May 2023 Volume 72 Issue 5  p647-826
https://www.jahonline.org/current

**Editorials**
International Collaboration to Support Research in Low- and Middle-Income Countries
Charles E. Irwin Jr.
Published in issue: May 2023
p649

**Original Articles**
Parental Perceptions Related to Co-Administration of Adolescent COVID-19 and Routine Vaccines
Courtney A. Gidengil, et al.
Published online: December 05, 2022
p667-673

Adolescent Self-Consent for COVID-19 Vaccination: Views of Healthcare Workers and Their Adolescent Children on Vaccination Autonomy
Published online: February 10, 2023
p674-681
Parental Engagement in Consent Processes for Enrollment in Biomedical HIV Prevention Trials: Implications for Minor Adolescents' Willingness to Participate
Amelia Knopf, et al.
Published online: January 14, 2023
p703-711

Journal of Artificial Intelligence Research
Vol. 77 (2023)
https://www.jair.org/index.php/jair
Contents
[New issue; No digest content identified]

Journal of Community Health
Volume 48, issue 2, April 2023
[Reviewed earlier]

Journal of Current Medical Research and Opinion
...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
March 8, 2023 Vol 6, No 03 (2023)
https://www.cmro.in/index.php/jcmro/issue/view/65
[Reviewed earlier]

Journal of Development Economics
Volume 162 May 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 18 Issue 1-2, February-April 2023
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
April 2023 - Volume 77 - 4
https://jech.bmj.com/content/77/4
[Reviewed earlier]
Journal of Evidence-Based Medicine
Volume 16, Issue 1  Pages: 1-100  March 2023
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 19, Issue 1 (2023)
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 2, May 2023
https://muse.jhu.edu/issue/50186
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 25, issue 2, April 2023
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 21, 2023  Issue 2
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 227, Issue 7, 1 April 2023
https://academic.oup.com/jid/issue/227/7
[Reviewed earlier]

Journal of International Development
Volume 35, Issue 3  Pages: 383-535  April 2023
https://onlinelibrary.wiley.com/toc/10991328/current
Special Issue: Brokering Development
[Reviewed earlier]

Journal of Medical Ethics
May 2023 - Volume 49 - 5
http://jme.bmj.com/content/current
Journal of Patient-Centered Research and Reviews
Volume 10, Issue 1 (2023)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
May 2023 Volume 256 p1-120
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 13 May 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
May/June 2023 - Volume 29 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 44, issue 1, March 2023
https://link.springer.com/journal/41271/volumes-and-issues/44-1
Articles
[Reviewed earlier]

Journal of the Royal Society – Interface
May 2023 Volume 20 Issue 202
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 30, Issue 2, March 2023
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
The Lancet
May 13, 2023 Volume 401 Number 10388 p1545-1628
https://www.thelancet.com/journals/lancet/issue/current
[New issue; No digest content identified]

The Lancet Child & Adolescent Health
May 2023 Volume 7 Number 5 p297-366, e11
https://www.thelancet.com/journals/lanchi/issue/current
Articles
*Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial*
Courtney P Olwagen, et al.
Open Access

Lancet Digital Health
May 2023 Volume 5 Number 5 e248-e327
https://www.thelancet.com/journals/landig/issue/current
Editorial
*Children must co-design digital health research*
The Lancet Digital Health

Health Policy
*The impact of commercial health datasets on medical research and health-care algorithms*
Isabelle Rose I Alberto, et al.

Lancet Global Health
May 2023 Volume 11 Number 5 e629-e795
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Apr 2023 Volume 23 Number 4 p381-508, e121-e165
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
May 2023 Volume 8 Number 5 e318-e390
Human pangenome

The human reference genome has been the backbone of human genomics since the release of the draft sequence in 2001. But it has its limitations: one genome cannot hope to capture the diversity of the human species. In this week’s issue, the Human Pangenome Reference Consortium presents the first draft human pangenome, which combines genetic material from 47 genetically diverse individuals to provide a more complete picture of the human genome. Two additional papers use this new
resource to study regions of the genome that include repetitive DNA: one looking at segmental duplications, the other at the short arms of acrocentric chromosomes. These results come from an early stage in the pangenome project, which ultimately aims to capture the genetic diversity of at least 350 individuals. The cover shows the pangenome wrapping a globe and uses a sequence tube map rendering of a pangenome graph relating ten haplotypes within the highly variable HLA-A locus on chromosome 6 created by Adam Novak at the University of California, Santa Cruz

Article
A draft human pangenome reference
Wen-Wei Liao...Benedict Paten
Nature, volume 617, pages 312–324 (2023) Published: 10 May 2023
Open Access
Abstract
Here the Human Pangenome Reference Consortium presents a first draft of the human pangenome reference. The pangenome contains 47 phased, diploid assemblies from a cohort of genetically diverse individuals. These assemblies cover more than 99% of the expected sequence in each genome and are more than 99% accurate at the structural and base pair levels. Based on alignments of the assemblies, we generate a draft pangenome that captures known variants and haplotypes and reveals new alleles at structurally complex loci. We also add 119 million base pairs of euchromatic polymorphic sequences and 1,115 gene duplications relative to the existing reference GRCh38. Roughly 90 million of the additional base pairs are derived from structural variation. Using our draft pangenome to analyse short-read data reduced small variant discovery errors by 34% and increased the number of structural variants detected per haplotype by 104% compared with GRCh38-based workflows, which enabled the typing of the vast majority of structural variant alleles per sample.

Discussion Excerpt: Concluding Text
....We acknowledge that references generated from the 1KG samples alone are insufficient to capture the extent of sequence diversity in the human population. To ensure that we are able to maximize our surveys of sample diversity while abiding by principles of community engagement and avoiding extractive practices, we will broaden our efforts to recruit new participants to improve the representation of human genetic diversity. A richer human reference map promises to improve our understanding of genomics and our ability to predict, diagnose and treat disease. A more diverse human reference map should also help ensure that the eventual applications of genomic research and precision medicine are effective for all populations. We recognize that the value of this project will partly be in the future establishment of new standards for how we capture variant diversity, the opportunity to disseminate science into diverse communities and continued efforts to engage with diverse voices in this ambitious goal to build a common global reference resource. The methods we are developing should prove valuable for other species. Indeed, other groups are pioneering such efforts. In parallel with our efforts to obtain a more comprehensive collection of diverse and highly accurate human reference genomes, we anticipate further optimization and rapid improvement of the pangenome reference, enabling an increasingly broad set of applications and use cases for both the research and clinical communities.

First human ‘pangenome’ aims to catalogue genetic diversity
Researchers release draft results from an ongoing effort to capture the entirety of human genetic variation NEWS
Layal Liverpool
[Excerpt; Concluding text]
...Ethical considerations
However, some researchers — including Fox — are concerned that the project risks repeating ethically questionable practices from other large-scale genetic-diversity projects. For instance, the Human Genome Diversity Project in the 1990s and the ongoing All of Us Research Program received criticism, including from US-based tribes, for failing to engage sufficiently with members of the communities whose DNA they were sampling. These included people belonging to marginalized groups usually under-represented in human genetic research.

“We will, of course, advance knowledge of human structural variation with new data sets and new tools. The progress we should be striving for, however, is the equitable engagement of under-represented communities in this work from the ground up,” says Krystal Tsosie, a genetic epidemiologist and bioethicist at Arizona State University in Tempe. Tsosie is also co-founder of the Native BioData Consortium, a non-profit research institute in Eagle Butte, South Dakota, led by Indigenous scientists and tribal members. “If the research is not benefiting the diverse communities first and foremost, then we are doing something fundamentally wrong here,” she says.

Fox, who is on the board of the Native BioData Consortium, agrees. He is concerned that data from the Human Pangenome Reference Project, which is funded by the US National Institutes of Health, could be used by the pharmaceutical industry for commercial purposes — as has happened in the past — without tangible benefits to the study participants or their communities.

Revisiting consent

Latifa Jackson, a geneticist at Howard University in Washington DC, points out that the 1000 Genomes Project relied partly on samples collected many years before it launched. “I am concerned that many of the participating pangenome locations have samples that were collected in the 1980s under very different political and social structures,” she says. “We need to revisit ideas of consent, especially for samples collected 30–40 years ago under very different power structures.”

“We recognize that this work is at the forefront of genomic research and has specific features, including open access of data, that warrant a great deal of consideration, and that the applications can raise ethical, legal and social issues,” Kenny said at the press conference. “We have drawn not only from our own expertise, but also built on the work of scholars and organizations throughout the world, to be aware of the many pitfalls and to systematically review other efforts for lessons learned, that we can bring into this new initiative.”

Kenny added that the pangenome consortium is hoping to recruit new study participants as part of its effort to maximize diversity among the planned 350 genomes. These will include participants obtained “through a large health system in an urban city like New York, which has people from almost every country of the world through processes of diaspora and migration”, said Kenny.
Code deposition is unskippable

As computational analysis becomes ever-more ubiquitous for researchers, the deposition of the underlying code is now an expected part of publication. Shortcomings in code sharing can lead to delays in peer review and publication, as well as reproducibility issues that are easily avoided with author preparation.

Nature Human Behaviour
Volume 7 Issue 4, April 2023
https://www.nature.com/nathumbehav/volumes/7/issues/4
[Reviewed earlier]

Nature Medicine
Volume 29 Issue 4, April 2023
https://www.nature.com/nm/volumes/29/issues/4
[Reviewed earlier]

Nature Reviews Drug Discovery
Volume 22 Issue 5, May 2023
https://www.nature.com/nrd/volumes/22/issues/5
Comment 28 Feb 2023
The opportunity for greater patient and public involvement and engagement in drug development and regulation
Patients and the wider public are beneficiaries of scientific research that leads to new drugs and medical technologies, but they can and should be able to contribute to these advances through participation in clinical studies, co-design of research and input into regulatory processes. Olalekan Lee Aiyegbusi, Samantha Cruz Rivera, Melanie J. Calvert

Nature Reviews Genetics
Volume 24 Issue 5, May 2023
https://www.nature.com/nrg/volumes/24/issues/5
[New issue; No digest content identified]

Nature Reviews Immunology
Volume 23 Issue 4, April 2023
https://www.nature.com/nri/volumes/23/issues/4
[Reviewed earlier]

New England Journal of Medicine
May 11, 2023 Vol. 388 No. 19
Clinical Practice
Human Papillomavirus Vaccination
L.E. Markowitz and E.R. Unger

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 13 May 2023]
[No new digest content identified]

Pediatrics
Volume 151, Issue 5  May 2023
https://publications.aap.org/pediatrics/issue/151/5
[Reviewed earlier]

PharmacoEconomics
Volume 41, issue 5, May 2023
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 13 May 2023)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 13 May 2023)
[No new digest content identified]

PLOS Global Public Health
https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 13 May 2023)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 13 May 2023)
[No new digest content identified]
PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 13 May 2023)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 13 May 2023]
Why we should care about moral foundations when preparing for the next pandemic: Insights from Canada, the UK and the US
Lizette Pizza, Samuel Ronfard, John D. Coley, Deborah Kelemen
Research Article | published 12 May 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0285549

W. Kip Viscusi
Research Article | published 11 May 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0284273

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 13 May 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
May 9, 2023 | vol. 120 | no. 19
https://www.pnas.org/toc/pnas/120/19
[New issue; No digest content identified]

PNAS Nexus
Volume 2, Issue 4, April 2023
https://academic.oup.com/pnasnexus/issue
[Reviewed earlier]

Prehospital & Disaster Medicine
Volume 38 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 170  May 2023
Evaluation of behavioral economic strategies to raise influenza vaccination rates across a health system: Results from a randomized clinical trial

Peter G. Szilagyi, Alejandra Casillas, O. Kenrik Duru, Michael K. Ong, ... Carlos Lerner

Article 107474

Proceedings of the Royal Society B
10 May 2023  Volume 290  Issue 1998
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 218  Pages 1-208 (May 2023)
[Reviewed earlier]

Public Health Ethics
Volume 16, Issue 1, April 2023
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 138 Issue 2, March/April 2023
https://journals.sagepub.com/toc/phrg/138/2
[Reviewed earlier]

Qualitative Health Research
Volume 33 Issue 5, April 2023
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 19 Issue 2, April 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 13 May 2023]
[No new digest content identified]
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en

Selected Articles
[No new digest content identified]

Risk Analysis
Volume 43, Issue 5  Pages: 867-1091  May 2023
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 13 May 2023]
[No new digest content identified]

Science
Volume 380| Issue 6645| 12 May 2023
https://www.science.org/toc/science/current
[New issue; No digest content identified]

Science and Engineering Ethics
Volume 29, issue 3, June 2023
[Reviewed earlier]

Science Translational Medicine
Volume 15| Issue 695| 10 May 2023
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Scientific Reports
https://www.nature.com/srep/articles?type=article
[Accessed 13 May 2023]
[No new digest content identified]

Social Science & Medicine
Volume 322  April 2023
Theoretical Medicine and Bioethics
Volume 44, April 2023, Issue 2
Special Issue: Controversial Arguments in Bioethics

Travel Medicine and Infectious Diseases
Volume 52 March–April 2023
[Reviewed earlier]

Tropical Medicine & International Health
Volume 28, Issue 5 Pages: i-iv, 343-418 May 2023
https://onlinelibrary.wiley.com/toc/13653156/current
[New issue; No digest content identified]

Vaccine
Volume 41, Issue 17 Pages 2729-2878 (24 April 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/17
Selected Content
Research article Open access
Divergent COVID-19 vaccine policies: Policy mapping of ten European countries
Robin van Kessel, Rebecca Forman, Ricarda Milstein, Alicja Mastylak, ... Elias Mossialos
Pages 2804-2810

Research article Open access
Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust
Bo Hu, Wei Yang, Paul Bouanchaud, Yolanda Chongo, ... Marcos Chissano
Pages 2846-2852

Research article Full text access
Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication
Dror Walter, Yotam Ophir, Hui Ye
Pages 2868-2877
A Case-Control Study on Factors of HPV Vaccination for Mother and Daughter in China
by Linyi Chen

Value in Health
May 2023 Volume 26 Issue 5 p617-790
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

Contents [click to move among sections]
:: Coronavirus [COVID-19]
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 13 May 2023]
Selected Research
[No new digest content identified]

medRxiv
https://www.medrxiv.org/content/about-medrxiv
[Accessed 13 May 2023]
[Filter: All articles]
Selected Research
Success in vaccination programming through community health workers: A case study of Nepal, Senegal, and Zambia
Emily Ogutu, Anna S. Ellis, Kyra A. Hester, Katie Rodriguez, Zoe Sakas, Chandni Jaishwal, Chenmua Yang, Sameer Dixit, Anindya S. Bose, Moussa Sarr, William Kilembe, Robert A. Bednarczyk, Matthew C. Freeman
medRxiv 2023.05.05.23289567; doi: https://doi.org/10.1101/2023.05.05.23289567
Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2021
Radhika Gharpure, Anna N. Chard, Maria Cabrera Escobar, Weigong Zhou, Joseph S. Bresee, Eduardo Aziz-Baumgartner, Sarah W. Pallas, Kathryn E. Lafond
medRxiv 2023.05.08.23289683; doi: https://doi.org/10.1101/2023.05.08.23289683

ChatGPT in medical literature – a concise review and SWOT analysis
Daniel Gödde, Sophia Nöhl, Carina Wolf, Yannik Rupert, Lukas Rimkus, Jan Ehlers, Frank Breuckmann, Timur Sellmann
medRxiv 2023.05.06.23289608; doi: https://doi.org/10.1101/2023.05.06.23289608

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 13 May 2023]
[Provider Filter: OSF Pre-prints  Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]
We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. If this continues, we may decide to no longer monitor this resource.

Measuring Media Freedom
Christopher Barrie, et al.
Abstract
The ability of news media to criticize government is a core pillar of media freedom and is often taken as evidence of meaningful democratization. Existing indices typically use scoring criteria or expert surveys to develop over-time measures of media freedom. In this article, we use the largest existing dataset of Arabic-language news to evaluate how political reporting about the government changes over the course of successful and failed democratic transitions in Egypt and Tunisia. Using entirely unsupervised ALC word-embedding techniques, we demonstrate how to generate temporally granular measurements of media criticism that closely correlate with measurements derived from expert surveys for both countries. Crucially, the technique we propose is computationally inexpensive, open-source, and cost-free—making it eminently scalable. Our work therefore points to new possibilities in the monitoring and measurement of media capture within authoritarian and transitional settings.

Exploring the Dimensions of Responsible Research Systems and Cultures: A Scoping Review
Sarahanne Miranda Field, et al.
Last edited: May 10, 2023 UTC
Social and Behavioral Sciences Science and Technology Studies
Abstract
The responsible conduct of research is foundational to the production of valid and trustworthy research. Despite this, our grasp of what dimensions responsible research (RR) might contain – and how it differs across disciplines (i.e., how it is conceptualized and operationalized) – is tenuous. Moreover, many initiatives related to developing and maintaining RR are developed within disciplinary and institutional silos which naturally limits the benefits that RR practice can have. To this end, we are working to develop a better understanding of how RR is conceived and realized, both across disciplines, and across institutions in Europe. The first step in doing this is to scope existing knowledge on the topic, of which this scoping review is a part. We searched several electronic databases for relevant
published and grey literature. An initial sample of 715 articles was identified, with 75 articles included in the final sample for qualitative analysis. We find several dimensions of RR that are underemphasized or are excluded from the well-established World Conferences on Research Integrity Singapore Statement on Research Integrity (WCRI) and explore facets of these dimensions that find special relevance in a range of research disciplines.

**Wellcome Open Research**
https://wellcomeopenresearch.org/browse/articles
[Accessed 13 May 2023]

**Selected Research**

**Study Protocol** Open Access

**Carbon pricing, health co-benefits and trade-offs: protocol for a systematic framework synthesis** [version 1; peer review: awaiting peer review]
Soledad Cuevas, et al

**Abstract**
Carbon pricing is considered an important instrument in the fight against climate change (World Bank, 2022). In particular, many experts and stakeholders have called for the implementation of carbon pricing as a part of ambitious climate policy agendas (Hepburn et al., 2020). This requires consideration of the interactions of carbon pricing with other policies, as well as of the societal outcomes of carbon pricing. In particular, carbon pricing has been found to have potentially large health impacts, leading to important co-benefits as well as potentially some trade-offs (Parry et al., 2014), (Hasegawa et al., 2018). Information on health impacts of carbon pricing, their distribution and how they are affected by policy design is necessary in order to progress towards more socially sustainable and politically feasible policy design.

Recent reviews have focussed on various aspects of carbon pricing design and outcomes, synthesizing evidence on its effectiveness, equity impacts or societal perception (Boyce, 2018), (Green, 2021), (Maestre-Andrés et al., 2019). Others have reviewed the evidence on health co-benefits of mitigation, but do not analyse specific policies or issues of policy design Gao et al.(2018).

This review will narratively synthesize the evidence on the health impacts of carbon pricing between 2010 and 2021 and identify gaps in the literature. We will use a framework synthesis approach to analyse different categories of policy-relevant information in contexts where carbon pricing is implemented as part of wider, coordinated policy agendas or complex policy mixes. This includes for example impacts on health inequalities and how health co-benefits are affected by issues of policy design and policy interactions.

**Open Letter** Open Access

**REVISED - Towards an appropriate African framework for public engagement with human genome editing: a call to synergistic action** [version 2; peer review: 2 approved with reservations, 1 not approved]
Gerald Michael Ssebunnya

**Abstract**
The CRISPR-Cas9 system has revolutionised the biotechnology of human genome editing. Human germline gene editing promises exponential benefits to many in Africa and elsewhere, especially those affected by the highly prevalent monogenic disorders - for which, thanks to CRISPR, a relatively safe heritable radical therapy is a real possibility. Africa evidently presents a unique opportunity for empirical research in human germline gene editing because of its high prevalence of monogenic disorders. Critically, however, germline gene editing has raised serious ethical concerns especially because of the
significant risks of inadvertent and intentional misuse of its transgenerational heritability. Calls for due prudence have become even more pronounced in the wake of the 2018 case of He Jiankui’s ‘CRISPR’d babies’. Meanwhile, Africa is seriously lagging in articulating its position on human genome editing. Conspicuously, there has been little to no attempt at comprehensively engaging the African public in discussions on the promises and concerns about human genome editing. Thus, the echoing key question remains as to how Africa should prudently embrace and govern this revolutionary biotechnology. In this article, therefore, I lay the groundwork for the possible development of an appropriate African framework for public engagement with human genome editing and call upon all stakeholders to urgent synergistic action. I particularly highlight the World Health Organisation’s possible leadership role in promptly establishing the requisite expert working group for this urgent need.

* * * * *

**Think Tanks**

**Brookings**  [to 13 May 2023]
http://www.brookings.edu/
*Latest Research [Selected]*
No new digest content identified.

**Center for Global Development**  [to 13 May 2023]
https://www.cgdev.org/
*All Research [Selected]*
**POLICY PAPERS**
*Gender Integration in Multilateral Development Banks’ COVID-19 Response Efforts*
Shelby Bourgault et al.
May 11, 2023

   The COVID pandemic has had differential effects by gender, with women experiencing higher job and income loss, increased rates of domestic violence, and mounting care burdens. We examine the extent to which MDB COVID response projects incorporated gender elements and highlight the gaps in those effo...

**Chatham House**  [to 13 May 2023]
https://www.chathamhouse.org/
*Selected Analysis, Comment, Events*
No new digest content identified.

**CSIS**  [to 13 May 2023]
https://www.csis.org/
*Selected Reports, Events*
No new digest content identified.
**Kaiser Family Foundation**  [to 13 May 2023]
https://www.kff.org/search/?post_type=press-release

*Newsroom*

**After the COVID-19 Public Health Emergency Ends on May 11, Some Consumers Could Face High Prices for COVID-19 Testing**

May 8, 2023  *News Release*

After the public health emergency ends on May 11, private health plans will no longer be required to cover the full cost of COVID-19 tests ordered or administered by a clinician or to reimburse consumers for at-home rapid tests. To estimate what consumers might have to pay for tests, KFF’s...

---

**McKinsey Global Institute**
https://www.mckinsey.com/mgi/overview

*Latest Research*

No new digest content identified.

---

**ODI [Overseas Development Institute]**  [to 13 May 2023]

*Publications [Selected]*

No new digest content identified.

---

**Pew Research Center**  [to 13 May 2023]
https://www.pewresearch.org/

*Latest Publications [Selected]*

No new digest content identified.

---

**Rand**  [to 13 May 2023]
https://www.rand.org/pubs.html

*Published Research [Selected]*

**Dissertation**

**Beliefs, Needs, and Participation: Aligning Risk Governance and Decision Making Under Deep Uncertainty Methods**

Explores three ways that incorporating social heterogeneity derived from risk governance principles can enhance the application of decision making under deep uncertainty-based analyses of disasters. May 11, 2023

*Journal Article*

**Risk Perception of the COVID-19 Vaccines: Revisiting the Psychometric Paradigm**

Americans’ concerns about the risks of vaccination are rising in recent years. A national survey (N=1025) conducted in August 2021 reflects this trend in risk perception of the COVID-19 vaccines. May 9, 2023

Jody Chin Sing Wong, Janet Z. Yang

---

**Urban Institute**  [to 13 May 2023]
https://www.urban.org/publications
New Research Publications - Selected

World Economic Forum [to 13 May 2023]
https://agenda.weforum.org/news/
Media
No new digest content identified.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::
Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *